Dr. Edward J. Kim
Claim this profileUniversity of California Davis Comprehensive Cancer Center
About Edward J. Kim
Education:
- Earned an A.B. in Chemistry from Harvard University, Cambridge, MA (1997).
- Received M.D. and Ph.D. from Stony Brook University, Stony Brook, NY (2005, 2003 respectively).
Experience:
- Completed Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan, Ann Arbor, MI (2005-2011).
- Serves as Medical Director at UC Davis Comprehensive Cancer Center’s Office of Clinical Research.
- Holds the position of Associate Professor of Medicine, specializing in gastrointestinal malignancies.
- Actively involved in clinical and laboratory research, focusing on novel treatments and patient-derived models for pancreatic cancer.
Area of expertise
Pancreatic Cancer
Edward J. Kim has run 7 trials for Pancreatic Cancer. Some of their research focus areas include:
Liver Cancer
Edward J. Kim has run 6 trials for Liver Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of California Davis Comprehensive Cancer Center
Fremont - Rideout Cancer Center
Clinical Trials Edward J. Kim is currently running
Cetuximab + Pembrolizumab
for Head and Neck Cancer
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting
2 awards
Phase 3
16 criteria
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting
1 award
Phase 2 & 3
20 criteria
More about Edward J. Kim
Clinical Trial Related
9 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Edward J. Kim has experience with
- Nivolumab
- Cisplatin
- Gemcitabine
- Nab-paclitaxel
- Radiation Therapy
- Hypofractionated Radiation Therapy
Breakdown of trials Edward J. Kim has run
Pancreatic Cancer
Liver Cancer
Gallbladder Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Edward J. Kim specialize in?
Edward J. Kim focuses on Pancreatic Cancer and Liver Cancer. In particular, much of their work with Pancreatic Cancer has involved PD-L1 positive patients, or patients who are Stage IV.
Is Edward J. Kim currently recruiting for clinical trials?
Yes, Edward J. Kim is currently recruiting for 9 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Edward J. Kim has studied deeply?
Yes, Edward J. Kim has studied treatments such as Nivolumab, Cisplatin, Gemcitabine.
What is the best way to schedule an appointment with Edward J. Kim?
Apply for one of the trials that Edward J. Kim is conducting.
What is the office address of Edward J. Kim?
The office of Edward J. Kim is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.